Bladder Cancer

Management and Future Directions{A figure is presented}

Christopher P Evans, Frans M J Debruyne, Heather Payne, Eduardo Solsona, Pierre Teillac, Andrea Tubaro

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Bladder cancer accounts for approximately 5-10% of all cancers in the United States and Europe and is the fourth most common malignancy among men. The incidence of bladder cancer increases with age and risk can be exacerbated by smoking, exposure to industrial carcinogens, and infection with schistosomiasis. Optimal patient management requires an accurate knowledge of the stage and grade of the disease, and an appraisal of the risk of progression and recurrence is required to plan the best course of treatment. At every diagnostic and therapeutic step there exist opportunities to optimise outcomes. Recent advances in the management of bladder cancer include the use of fluoroscopic and cystoscopic detection, intravesical therapy, neoadjuvant chemotherapy, and bladder-sparing multimodal therapy. Moreover, new understanding of molecular markers may provide more accurate prognosis in the future and enable treatment to be tailored to individual patients. The urologic community should strive to consider and implement new approaches in the longitudinal care of patients with bladder cancer.

Original languageEnglish (US)
Pages (from-to)365-373
Number of pages9
JournalEuropean Urology, Supplements
Volume6
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Urinary Bladder Neoplasms
Neoadjuvant Therapy
Schistosomiasis
Therapeutics
Carcinogens
Neoplasms
Patient Care
Urinary Bladder
Smoking
Recurrence
Drug Therapy
Direction compound
Incidence
Infection

Keywords

  • Biomarkers
  • Bladder cancer
  • Bladder-sparing
  • Chemoradiation
  • Cystectomy
  • Fluorescence cystoscopy
  • Intravesical therapy
  • Neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Urology

Cite this

Bladder Cancer : Management and Future Directions{A figure is presented}. / Evans, Christopher P; Debruyne, Frans M J; Payne, Heather; Solsona, Eduardo; Teillac, Pierre; Tubaro, Andrea.

In: European Urology, Supplements, Vol. 6, No. 3, 03.2007, p. 365-373.

Research output: Contribution to journalArticle

Evans, CP, Debruyne, FMJ, Payne, H, Solsona, E, Teillac, P & Tubaro, A 2007, 'Bladder Cancer: Management and Future Directions{A figure is presented}', European Urology, Supplements, vol. 6, no. 3, pp. 365-373. https://doi.org/10.1016/j.eursup.2006.12.005
Evans, Christopher P ; Debruyne, Frans M J ; Payne, Heather ; Solsona, Eduardo ; Teillac, Pierre ; Tubaro, Andrea. / Bladder Cancer : Management and Future Directions{A figure is presented}. In: European Urology, Supplements. 2007 ; Vol. 6, No. 3. pp. 365-373.
@article{d9a0d1b99233482c9d54cc09ea5369ed,
title = "Bladder Cancer: Management and Future Directions{A figure is presented}",
abstract = "Bladder cancer accounts for approximately 5-10{\%} of all cancers in the United States and Europe and is the fourth most common malignancy among men. The incidence of bladder cancer increases with age and risk can be exacerbated by smoking, exposure to industrial carcinogens, and infection with schistosomiasis. Optimal patient management requires an accurate knowledge of the stage and grade of the disease, and an appraisal of the risk of progression and recurrence is required to plan the best course of treatment. At every diagnostic and therapeutic step there exist opportunities to optimise outcomes. Recent advances in the management of bladder cancer include the use of fluoroscopic and cystoscopic detection, intravesical therapy, neoadjuvant chemotherapy, and bladder-sparing multimodal therapy. Moreover, new understanding of molecular markers may provide more accurate prognosis in the future and enable treatment to be tailored to individual patients. The urologic community should strive to consider and implement new approaches in the longitudinal care of patients with bladder cancer.",
keywords = "Biomarkers, Bladder cancer, Bladder-sparing, Chemoradiation, Cystectomy, Fluorescence cystoscopy, Intravesical therapy, Neoadjuvant chemotherapy",
author = "Evans, {Christopher P} and Debruyne, {Frans M J} and Heather Payne and Eduardo Solsona and Pierre Teillac and Andrea Tubaro",
year = "2007",
month = "3",
doi = "10.1016/j.eursup.2006.12.005",
language = "English (US)",
volume = "6",
pages = "365--373",
journal = "European Urology, Supplements",
issn = "1569-9056",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Bladder Cancer

T2 - Management and Future Directions{A figure is presented}

AU - Evans, Christopher P

AU - Debruyne, Frans M J

AU - Payne, Heather

AU - Solsona, Eduardo

AU - Teillac, Pierre

AU - Tubaro, Andrea

PY - 2007/3

Y1 - 2007/3

N2 - Bladder cancer accounts for approximately 5-10% of all cancers in the United States and Europe and is the fourth most common malignancy among men. The incidence of bladder cancer increases with age and risk can be exacerbated by smoking, exposure to industrial carcinogens, and infection with schistosomiasis. Optimal patient management requires an accurate knowledge of the stage and grade of the disease, and an appraisal of the risk of progression and recurrence is required to plan the best course of treatment. At every diagnostic and therapeutic step there exist opportunities to optimise outcomes. Recent advances in the management of bladder cancer include the use of fluoroscopic and cystoscopic detection, intravesical therapy, neoadjuvant chemotherapy, and bladder-sparing multimodal therapy. Moreover, new understanding of molecular markers may provide more accurate prognosis in the future and enable treatment to be tailored to individual patients. The urologic community should strive to consider and implement new approaches in the longitudinal care of patients with bladder cancer.

AB - Bladder cancer accounts for approximately 5-10% of all cancers in the United States and Europe and is the fourth most common malignancy among men. The incidence of bladder cancer increases with age and risk can be exacerbated by smoking, exposure to industrial carcinogens, and infection with schistosomiasis. Optimal patient management requires an accurate knowledge of the stage and grade of the disease, and an appraisal of the risk of progression and recurrence is required to plan the best course of treatment. At every diagnostic and therapeutic step there exist opportunities to optimise outcomes. Recent advances in the management of bladder cancer include the use of fluoroscopic and cystoscopic detection, intravesical therapy, neoadjuvant chemotherapy, and bladder-sparing multimodal therapy. Moreover, new understanding of molecular markers may provide more accurate prognosis in the future and enable treatment to be tailored to individual patients. The urologic community should strive to consider and implement new approaches in the longitudinal care of patients with bladder cancer.

KW - Biomarkers

KW - Bladder cancer

KW - Bladder-sparing

KW - Chemoradiation

KW - Cystectomy

KW - Fluorescence cystoscopy

KW - Intravesical therapy

KW - Neoadjuvant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=33846460824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846460824&partnerID=8YFLogxK

U2 - 10.1016/j.eursup.2006.12.005

DO - 10.1016/j.eursup.2006.12.005

M3 - Article

VL - 6

SP - 365

EP - 373

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 3

ER -